Development of cancer immunotherapy targeting for the immune responses in tumor stroma in non-small cell lung cancer
Description: In this study, to clarify the immune responses in tumor stroma in non-small cell lung cancer (NSCLC), we focused on a dominant stromal cell type, cancer-associated fibroblasts (CAFs). We examined the regulation of PD-L1 expression on CAFs and the clinical significance of PD-L1 expression on CAFs in NSCLC. As results, PD-L1 expression on CAFs is reversibly regulated by interferon-gamma. Patients with PD-L1-positive CAFs had significantly better prognosis (prolonged relapse-free survival after surgery) than patients with PD-L1-negative CAF, demonstrating that PD-L1 expression on CAFs is an independent prognostic biomarker. These results suggest that PD-L1 expression on CAFs indicates the induction of anti-tumor immune responses in NSCLC.
Amount: ¥4,810,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (C)
Start date: 2016-04-01
End date: 2019-03-31
Investigator: Koji Teramoto (lead)
Institution: Shiga University of Medical Science
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 6
Funder award ID: 16K10677
OpenAlex ID: G1959049461
